Dexamethasone isonicotinate is an anti-inflammatory, anti-allergic glucocorticoid that can be administered orally, by inhalation, topically, and parenterally. Its unintended mineralocorticoid action may cause salt and water retention.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Denosumab | The risk or severity of adverse effects can be increased when Denosumab is combined with Dexamethasone isonicotinate. |
| Peginterferon alfa-2a | The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Dexamethasone isonicotinate. |
| Interferon alfa-n1 | The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Dexamethasone isonicotinate. |
| Interferon alfa-n3 | The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Dexamethasone isonicotinate. |
| Peginterferon alfa-2b | The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Dexamethasone isonicotinate. |
| Interferon gamma-1b | The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Dexamethasone isonicotinate. |
| Interferon alfa-2a | The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Dexamethasone isonicotinate. |
| Gemtuzumab ozogamicin | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Dexamethasone isonicotinate. |
| Pegaspargase | The serum concentration of Dexamethasone isonicotinate can be increased when it is combined with Pegaspargase. |
| Interferon beta-1b | The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Dexamethasone isonicotinate. |
| Interferon alfacon-1 | The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Dexamethasone isonicotinate. |
| Rituximab | The risk or severity of adverse effects can be increased when Rituximab is combined with Dexamethasone isonicotinate. |
| Basiliximab | The risk or severity of adverse effects can be increased when Basiliximab is combined with Dexamethasone isonicotinate. |
| Muromonab | The risk or severity of adverse effects can be increased when Muromonab is combined with Dexamethasone isonicotinate. |
| Ibritumomab tiuxetan | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Dexamethasone isonicotinate. |
| Tositumomab | The risk or severity of adverse effects can be increased when Tositumomab is combined with Dexamethasone isonicotinate. |
| Alemtuzumab | The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Dexamethasone isonicotinate. |
| Alefacept | The risk or severity of adverse effects can be increased when Alefacept is combined with Dexamethasone isonicotinate. |
| Efalizumab | The risk or severity of adverse effects can be increased when Efalizumab is combined with Dexamethasone isonicotinate. |
| Antithymocyte immunoglobulin (rabbit) | The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Dexamethasone isonicotinate. |
| Interferon alfa-2b | The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Dexamethasone isonicotinate. |
| Daclizumab | The risk or severity of adverse effects can be increased when Daclizumab is combined with Dexamethasone isonicotinate. |
| Phenylalanine | The risk or severity of adverse effects can be increased when Phenylalanine is combined with Dexamethasone isonicotinate. |
| Cladribine | Dexamethasone isonicotinate may increase the immunosuppressive activities of Cladribine. |
| Carmustine | The risk or severity of adverse effects can be increased when Carmustine is combined with Dexamethasone isonicotinate. |
| Amsacrine | The risk or severity of adverse effects can be increased when Amsacrine is combined with Dexamethasone isonicotinate. |
| Bleomycin | The risk or severity of adverse effects can be increased when Bleomycin is combined with Dexamethasone isonicotinate. |
| Chlorambucil | The risk or severity of adverse effects can be increased when Chlorambucil is combined with Dexamethasone isonicotinate. |
| Raltitrexed | The risk or severity of adverse effects can be increased when Raltitrexed is combined with Dexamethasone isonicotinate. |
| Mitomycin | The risk or severity of adverse effects can be increased when Mitomycin is combined with Dexamethasone isonicotinate. |
| Bexarotene | The risk or severity of adverse effects can be increased when Bexarotene is combined with Dexamethasone isonicotinate. |
| Floxuridine | The risk or severity of adverse effects can be increased when Floxuridine is combined with Dexamethasone isonicotinate. |
| Tioguanine | The risk or severity of adverse effects can be increased when Tioguanine is combined with Dexamethasone isonicotinate. |
| Dexrazoxane | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Dexamethasone isonicotinate. |
| Streptozocin | The risk or severity of adverse effects can be increased when Streptozocin is combined with Dexamethasone isonicotinate. |
| Trifluridine | The risk or severity of adverse effects can be increased when Trifluridine is combined with Dexamethasone isonicotinate. |
| Gemcitabine | The risk or severity of adverse effects can be increased when Gemcitabine is combined with Dexamethasone isonicotinate. |
| Epirubicin | The risk or severity of adverse effects can be increased when Epirubicin is combined with Dexamethasone isonicotinate. |
| Chloramphenicol | The risk or severity of adverse effects can be increased when Chloramphenicol is combined with Dexamethasone isonicotinate. |
| Lenalidomide | The risk or severity of adverse effects can be increased when Lenalidomide is combined with Dexamethasone isonicotinate. |
| Altretamine | The risk or severity of adverse effects can be increased when Altretamine is combined with Dexamethasone isonicotinate. |
| Zidovudine | The risk or severity of adverse effects can be increased when Zidovudine is combined with Dexamethasone isonicotinate. |
| Oxaliplatin | The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Dexamethasone isonicotinate. |
| Fluorouracil | The risk or severity of adverse effects can be increased when Fluorouracil is combined with Dexamethasone isonicotinate. |
| Propylthiouracil | The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Dexamethasone isonicotinate. |
| Pentostatin | The risk or severity of adverse effects can be increased when Pentostatin is combined with Dexamethasone isonicotinate. |
| Linezolid | The risk or severity of adverse effects can be increased when Linezolid is combined with Dexamethasone isonicotinate. |
| Clofarabine | The risk or severity of adverse effects can be increased when Clofarabine is combined with Dexamethasone isonicotinate. |
| Pemetrexed | The risk or severity of adverse effects can be increased when Pemetrexed is combined with Dexamethasone isonicotinate. |
| Mycophenolate mofetil | The risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Dexamethasone isonicotinate. |
| Tretinoin | The metabolism of Tretinoin can be increased when combined with Dexamethasone isonicotinate. |
| Dacarbazine | The risk or severity of adverse effects can be increased when Dacarbazine is combined with Dexamethasone isonicotinate. |
| Temozolomide | The risk or severity of adverse effects can be increased when Temozolomide is combined with Dexamethasone isonicotinate. |
| Penicillamine | The risk or severity of adverse effects can be increased when Penicillamine is combined with Dexamethasone isonicotinate. |
| Azacitidine | The risk or severity of adverse effects can be increased when Azacitidine is combined with Dexamethasone isonicotinate. |
| Carboplatin | The risk or severity of adverse effects can be increased when Carboplatin is combined with Dexamethasone isonicotinate. |
| Dactinomycin | The risk or severity of adverse effects can be increased when Dactinomycin is combined with Dexamethasone isonicotinate. |
| Azathioprine | The risk or severity of adverse effects can be increased when Azathioprine is combined with Dexamethasone isonicotinate. |
| Hydroxyurea | The risk or severity of adverse effects can be increased when Hydroxyurea is combined with Dexamethasone isonicotinate. |
| Mycophenolic acid | The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Dexamethasone isonicotinate. |
| Topotecan | The risk or severity of adverse effects can be increased when Topotecan is combined with Dexamethasone isonicotinate. |
| Mercaptopurine | The risk or severity of adverse effects can be increased when Mercaptopurine is combined with Dexamethasone isonicotinate. |
| Thalidomide | The risk or severity of adverse effects can be increased when Thalidomide is combined with Dexamethasone isonicotinate. |
| Melphalan | The risk or severity of adverse effects can be increased when Melphalan is combined with Dexamethasone isonicotinate. |
| Fludarabine | The risk or severity of adverse effects can be increased when Fludarabine is combined with Dexamethasone isonicotinate. |
| Flucytosine | The risk or severity of adverse effects can be increased when Flucytosine is combined with Dexamethasone isonicotinate. |
| Capecitabine | The risk or severity of adverse effects can be increased when Capecitabine is combined with Dexamethasone isonicotinate. |
| Procarbazine | The risk or severity of adverse effects can be increased when Procarbazine is combined with Dexamethasone isonicotinate. |
| Arsenic trioxide | The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Dexamethasone isonicotinate. |
| Idarubicin | The risk or severity of adverse effects can be increased when Idarubicin is combined with Dexamethasone isonicotinate. |
| Estramustine | The risk or severity of adverse effects can be increased when Estramustine is combined with Dexamethasone isonicotinate. |
| Mitoxantrone | The risk or severity of adverse effects can be increased when Mitoxantrone is combined with Dexamethasone isonicotinate. |
| Lomustine | The risk or severity of adverse effects can be increased when Lomustine is combined with Dexamethasone isonicotinate. |
| Eculizumab | The risk or severity of adverse effects can be increased when Eculizumab is combined with Dexamethasone isonicotinate. |
| Decitabine | The risk or severity of adverse effects can be increased when Decitabine is combined with Dexamethasone isonicotinate. |
| Nelarabine | The risk or severity of adverse effects can be increased when Nelarabine is combined with Dexamethasone isonicotinate. |
| Stepronin | The risk or severity of adverse effects can be increased when Stepronin is combined with Dexamethasone isonicotinate. |
| Hydroxychloroquine | The risk or severity of adverse effects can be increased when Hydroxychloroquine is combined with Dexamethasone isonicotinate. |
| Castanospermine | The risk or severity of adverse effects can be increased when Castanospermine is combined with Dexamethasone isonicotinate. |
| Vorinostat | The risk or severity of adverse effects can be increased when Vorinostat is combined with Dexamethasone isonicotinate. |
| 2-Methoxyethanol | The risk or severity of adverse effects can be increased when 2-Methoxyethanol is combined with Dexamethasone isonicotinate. |
| Brequinar | The risk or severity of adverse effects can be increased when Brequinar is combined with Dexamethasone isonicotinate. |
| Pirfenidone | The risk or severity of adverse effects can be increased when Pirfenidone is combined with Dexamethasone isonicotinate. |
| Interferon alfa | The risk or severity of adverse effects can be increased when Interferon alfa is combined with Dexamethasone isonicotinate. |
| Glatiramer | The risk or severity of adverse effects can be increased when Glatiramer is combined with Dexamethasone isonicotinate. |
| Briakinumab | The risk or severity of adverse effects can be increased when Briakinumab is combined with Dexamethasone isonicotinate. |
| Human interferon omega-1 | The risk or severity of adverse effects can be increased when Human interferon omega-1 is combined with Dexamethasone isonicotinate. |
| Mepolizumab | The risk or severity of adverse effects can be increased when Mepolizumab is combined with Dexamethasone isonicotinate. |
| Abetimus | The risk or severity of adverse effects can be increased when Abetimus is combined with Dexamethasone isonicotinate. |
| Belatacept | The risk or severity of adverse effects can be increased when Belatacept is combined with Dexamethasone isonicotinate. |
| Bendamustine | The risk or severity of adverse effects can be increased when Bendamustine is combined with Dexamethasone isonicotinate. |
| Pralatrexate | The risk or severity of adverse effects can be increased when Pralatrexate is combined with Dexamethasone isonicotinate. |
| Wortmannin | The risk or severity of adverse effects can be increased when Wortmannin is combined with Dexamethasone isonicotinate. |
| Eribulin | The risk or severity of adverse effects can be increased when Eribulin is combined with Dexamethasone isonicotinate. |
| Belimumab | The risk or severity of adverse effects can be increased when Belimumab is combined with Dexamethasone isonicotinate. |
| Teriflunomide | The risk or severity of adverse effects can be increased when Teriflunomide is combined with Dexamethasone isonicotinate. |
| Carfilzomib | The risk or severity of adverse effects can be increased when Carfilzomib is combined with Dexamethasone isonicotinate. |
| Dimethyl fumarate | The risk or severity of adverse effects can be increased when Dimethyl fumarate is combined with Dexamethasone isonicotinate. |
| Obinutuzumab | The risk or severity of adverse effects can be increased when Obinutuzumab is combined with Dexamethasone isonicotinate. |
| Vedolizumab | The risk or severity of adverse effects can be increased when Vedolizumab is combined with Dexamethasone isonicotinate. |